Payment overview · 2025
General Payments
$144.26
8 reported records · 6 companies
Healthcare provider profile · identity verified
Andrea M Ely, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROELAND PARK, KS · NPI 1184734816
Verified facts
What the public records show
CMS Open Payments records show Andrea M Ely, M.D. received $144.26 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.08 | 29.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.04 | 19.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $22.51 | 15.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.46 | 13.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.52 | 12.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.65 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.26 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.08 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.08 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 673 | 174 |
| Losartan Potassium | Losartan Potassium | 518 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 439 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 116 |
| Alprazolam | Alprazolam | 315 | 60 |
| Gabapentin | Gabapentin | 314 | 86 |
| Alendronate Sodium | Alendronate Sodium | 288 | 85 |
| Trazodone Hcl | Trazodone Hcl | 237 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 65 |
| Omeprazole | Omeprazole | 219 | 58 |
| Lisinopril | Lisinopril | 214 | 55 |
| Carvedilol | Carvedilol | 189 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 46 |
| Metformin Hcl | Metformin Hcl | 180 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 51 |
| Simvastatin | Simvastatin | 152 | 45 |
| Sertraline Hcl | Sertraline Hcl | 145 | 47 |
| Bupropion Xl | Bupropion Hcl | 137 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 30 |
| Meloxicam | Meloxicam | 130 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 28 |
| Potassium Chloride | Potassium Chloride | 118 | 32 |
| Montelukast Sodium | Montelukast Sodium | 117 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 108 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 25 |
| Tramadol Hcl | Tramadol Hcl | 103 | 27 |
| Estradiol | Estradiol | 99 | 34 |
| Famotidine | Famotidine | 86 | 25 |
| Allopurinol | Allopurinol | 84 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 22 |
| Pregabalin | Pregabalin | 72 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Donepezil Hcl | Donepezil Hcl | 66 | 15 |
| Synthroid | Levothyroxine Sodium | 62 | 15 |
| Celecoxib | Celecoxib | 60 | 14 |
| Ozempic | Semaglutide | 60 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 58 | 20 |
| Irbesartan | Irbesartan | 56 | 12 |
| Glipizide Er | Glipizide | 52 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 48 |
| Spironolactone | Spironolactone | 51 | 12 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 17 |
| Eliquis | Apixaban | 46 | 13 |
| Valacyclovir | Valacyclovir Hcl | 46 | 19 |
| Furosemide | Furosemide | 45 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 14 |
| Valsartan | Valsartan | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Ondansetron Odt | Ondansetron | 36 | 19 |
| Prednisone | Prednisone | 36 | 25 |
| Diazepam | Diazepam | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Cephalexin | Cephalexin | 32 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 21 |
| Acyclovir | Acyclovir | 28 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Trimethoprim | Trimethoprim | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.26 · 8 records | Amgen Inc. | ABRYSVO, COMIRNATY, ELIQUIS, EVKEEZA, OTEZLA, PREVNAR 20, REPATHA, UBRELVY, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error